Alvine Pharmaceuticals Inc., a Palo Alto, Calif.-based drug company focused on Celiac disease, has secured nearly $8 million of a $21.33 million Series A round, according to a regulatory filing. Backers include Prospect Venture Partners and Sofinnova Ventures. (Source: PE Week Wire)